Cardiac & Tumor Markers
PSA Rapid Test
Detects Prostate-specific antigen. colloidal-gold. Specimen: WB / S / P.
| Target / Analyte | Prostate-specific antigen |
|---|---|
| Disease / Indication | Prostate cancer screening |
| Series | Cardiac & Tumor Markers |
| Method | colloidal-gold |
| Specimen | WB / S / P |
| Regulatory | CE |
| OEM/ODM | Available — private label & custom panel |
Direct Answer
This rapid test detects Prostate-specific antigen in WB / S / P to support Prostate cancer screening. It is a colloidal-gold screening test — a reactive result is presumptive and should be confirmed per the intended use.
Intended Use
Detection of prostate-specific antigen (PSA) for prostate cancer screening support.
Clinical Context
PSA is a prostate biomarker used in screening and monitoring; elevated PSA prompts further evaluation (biopsy).
Test Principle
Colloidal-gold immunochromatography (lateral flow). The device captures the target analyte (antigen or antibody) on a membrane via labeled antibodies, producing a visible test line within minutes. Qualitative or semi-quantitative, intended as a screening/triage aid — not a replacement for confirmatory laboratory testing.
Limitations
Elevated PSA is not specific to cancer (BPH, prostatitis); POC semi-quantitative results are screening-grade.
Procurement
Specimen: whole blood / serum / plasma. Format: cassette / strip. CE-marked line.
Interpretation
| Result | Lines | Meaning |
|---|---|---|
| Positive | Test + control line | Target detected (presumptive positive) |
| Negative | Control line only | Below cut-off / not detected |
| Invalid | No control line | Repeat with a new device |
Documentation & quotation — datasheet, IFU, MOQ and OEM/ODM options on request.
Last reviewed: 2026-09-12